... in immunocompetent patients have been increasingly described. PBL shares common morphological and immunohistochemical features with diffuse large B-cell lymphoma (DLBCL) and multiple myeloma (MM). Due to the rarity of PBL, there is no current consensual standard therapy available. As a result, PBL treatment...

... survival and subsequently high cumulative doses of bisphosphonates, multiple myeloma patients have the highest risk of developing BRONJ of all patients treated with bisphosphonates. The purpose of the present study was to evaluate the incidence and risk factors for BRONJ in multiple myeloma patients after...

...’ subjects. With the introduction of the immunomodulatory drugs thalidomide and lenalidomide, a novel class of compounds was integrated into therapy of multiple myeloma. Either drug may be delivered for a prolonged time; however fatigue, constipation and neuropathy prevent thalidomide from serving...

...Wolfgang Knauf; Lenka Kellermann; Wolfgang Poenisch; Hermann Einsele; Christian Straka; Claas Frohn; Hartmut Goldschmidt Background: The present survey was undertaken to gain insights in the changes of disease management of multiple myeloma (MM) over time and the implementation of new guidelines...

...Stefan Schmitt; Anthony D. Ho; Hartmut Goldschmidt Background: Multiple myeloma as the second most common hematological malignancy is characterized by proliferation of monoclonal plasma cells. This entity still remains a non-curable disorder leading, amongst others, to complications as myeloma bone...

... of multiple myeloma (MM). Both types of cutaneous plasmacytoma are commonly observed in the terminal stages of MM. Case Report: We present the case of a 37-year-old Turkish man diagnosed with lambda light chain MM. The patient had numerous firm plaque-shaped cutaneous lesions on the left side of the chest...

...Dirk M. Henrich; Martin Hoffmann; Michael Uppenkamp; Raoul Bergner Background: Bone disease is a feature of multiple myeloma (MM). Many patients have compromised renal function and sometimes develop end-stage renal disease (ESRD). For these patients, presently there exists no approved...

... enzyme immunoassay with competitive inhibition. Sera of 81 healthy subjects, 42 patients with renal failure, 108 patients with monoclonal gammopathies [3 monoclonal gammopathies of undetermined significance (MGUS), 91 multiple myeloma (MM), 14 macroglobulinemia (MG)], and 11 patients with non-Hodgkin...

...M.E. Heim; M.R. Clemens; W. Queißer; M. Pecherstorfer; Ch. Boewer; M. Herold; A. Franke; Z. Herrmann; R. Loose; L. Edler Background : Characteristic features of multiple myeloma are bone resorption, osteoporosis and osteolytic lesions. Bisphosphonates can inhibit osteoclast activity and bone...

...H. Goldschmidt; U. Hegenbart; R. Haas; W. Hunstein The median survival of conventionally treated patients with multiple myeloma is 3 years. Modifications of conventional chemotherapy and the administration of interferon-α have failed to show an improved survival in most randomized trials. Therapy...

...R. Fuchs; R. Reisner; U. Hellerich Background: Diagnostic problems may arise in multiple myeloma if the morphological pattern is not typical for a plasmocytoma and if it is not possible to assign a specimen to one of the well-known cytological subtypes of this disease. Such difficulties were met...

...A. Heyll; C. Aul; V. Runde; M. Thomas; W. Schneider Since 1987, about 250 patients undergoing allogeneic or autologous bone marrow transplantation (BMT) for multiple myeloma have been reported. Most of the patients belonged to advanced tumor stages and had received extensive chemotherapy prior...

.... Stenzinger; C. Tirier; H. Wagner; H.J. Weh; J. Wysk 277 untreated multiple myeloma patients of stage I (n = 33), II (n = 106) and III (n = 138) entered the study. Patients of stage II presenting a progressive tumor (n = 64) initially or during observation (n = 14) were treated with MivP (remissions: 61...

...D. Peest; H. Deicher; R. Coldewey; I.-M. v. Broen; U. Cammerer; R. Hein; L. Hoffmann; H. Konyar; E.D. Kreuser; J. Selbach; H.J. Weh 136 untreated multiple myeloma patients of stage II and III were collected in the study. 37/51 stage II patients had progressive disease and were treated...

...P. Preis; W. Scheithauer; E. Fritz; C. Zielinski; I. Kuehrer; A. Cortelezzi; E. Polli; L. Baldini; R. Pirker; A. Kriegisch; H. Ludwig Fifty-two previously untreated patients with multiple myeloma were randomized to either a combination of recombinant interferon (rIFN) alpha-2 and chemotherapy...

..., instructions or products referred to in the content or advertisements. Multiple myeloma Randomized trial Maintenance therapy Onkologie 9: 168-169 (3/1986) Current Results of a Multicenter Trial in Multiple Myeloma D. Peest, H.-J. Schmoll, I. Schedel, H. Deicher, J. Boll, U. Essers, H. Gamm, S. Glück...

...Wolfgang Ulrich Knauf; Burkhard Otremba; Friedrich Overkamp; Martin Kornacker Background: In Germany, bortezomib is approved for the therapy of relapsed multiple myeloma since 2004. The data which had led to the approval were based on strictly selected patients. However, no data had been recorded...

...Martin Görner; Ernst Späth-Schwalbe Multiple myeloma, an incurable malignancy of plasma cells, is a disease of the elderly. In younger patients, significant therapeutic progress has been achieved, but survival outcomes remain unacceptably low in older adults with multiple myeloma. Diverse factors...